CD274 and non-small cell lung carcinoma: Over the past decade, the application of immune checkpoint inhibitors (ICIs), which block programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling, has dramatically reshaped therapeutic approaches to advanced NSCLC (2).